Document is current
Any future updates will be listed below
-
Authors
Anholm, Christian https://orcid.org/0000-0002-2669-1642
Kumarathurai, Preman
Jürs, Anders
Pedersen, Lene Rørholm
Nielsen, Olav Wendelboe
Kristiansen, Ole Peter
Fenger, Mogens
Holst, Jens Juul
Madsbad, Sten
Sajadieh, Ahmad
Haugaard, Steen Bendix
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01595789 at ClinicalTrials.govDocuments that mention this clinical trial
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol
https://doi.org/10.1136/bmjopen-2014-005942
Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease
https://doi.org/10.1186/s13098-019-0438-6
Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
https://doi.org/10.1186/s12933-020-01205-2
-
Funding
Funding for this research was provided by:
Novo Nordisk
Hjerteforeningen
A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
Dept. of internal medicine, University Hospital of Copenhagen Amager
The Clinical Research Center, University Hospital of Copenhagen Hvidovre
The Bispebjerg Hospital Research Foundation
- License Information
-
More Information
Article History
Received: 25 February 2019
Accepted: 17 May 2019
First Online: 31 May 2019
Ethics approval and consent to participate
: The study has been approved by the Regional Committee on Biomedical Research Ethics of the Capital Region of Denmark informed consent was obtained from all participants.
: Not applicable.
: CA: Advisory board and lecture fees: Novo Nordisk. PK: none. AJ: none. LRP: share owner: Novo Nordisk. OWN: funding of educational and research tasks from ResMed and participated on advisory boards for Novartis. OPK: none. MF: none. JJH: none. SM: Advisory boards: AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Eli Lilly; Intarcia Therapeutics; Johnson & Johnson; Merck Sharp & Dohme; Novartis; Novo Nordisk; Sanofi Aventis. Lecture fees: AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Eli Lilly; Merck Sharp & Dohme; Novartis; Novo Nordisk; Sanofi Aventis. Research Grant Recipient: Novo Nordisk. AS: none. SBH: has received funding of educational and research tasks from Novo Nordisk, Abbott, Eli Lilly, Pfizer, Boehringer Ingelheim, Bristol-Meyers Squibb, and Merck Sharp & Dohme.
